Notable examples of each category include the selection of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors (EGFR-TKIs) such as Osimertinib in Lung cancer [2], selection of the pan-cancer drug Larotrectinib in malignancies which harbor NTRK fusions [3] or selection of the immune checkpoint inhibitor (ICI) Pembrolizumab in multiple cancers based on PD-L1 expression [4], microsatellite instability (MSI) or deficiency in Mismatch Repair (dMMR) genes [5] as well as tumor mutation burden (TMB) [6]. The gene discussed is CD274; the disease is neoplasm.